Moderate

Peptic ulcer disease (PUD) & H. pylori eradication (gastric/duodenal ulcer)

Gastric ulcer, duodenal ulcer, H. pylori, NSAID ulcer, dyspepsia · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Mucosal break >5 mm in stomach or duodenum penetrating muscularis mucosae. Main causes: H. pylori and NSAID/aspirin use (together ~90%); also stress, Zollinger-Ellison, malignancy. Presents with epigastric pain, dyspepsia, or complications (bleeding, perforation, obstruction). H. pylori eradication heals ulcers and prevents recurrence.

Red flags

  • Haematemesis / melaena / haemodynamic instability (bleeding ulcer)
  • Sudden severe generalised abdominal pain + rigidity (perforation)
  • Persistent vomiting + succussion splash (gastric outlet obstruction)
  • Weight loss, anaemia, dysphagia, new dyspepsia age >55 (malignancy)
  • Gastric ulcer not re-scoped to confirm healing (missed cancer)

Assessment

Differential diagnosis

  • Functional dyspepsia (no ulcer at OGD)
  • GORD
  • Gastric or pancreatic malignancy (gastric ulcer must be biopsied/followed up)
  • Biliary colic / cholecystitis
  • Acute pancreatitis
  • Mesenteric ischaemia, AAA
  • Myocardial infarction (inferior)
  • Zollinger-Ellison syndrome (multiple/refractory/distal ulcers)

Investigations

  • H. pylori testing: stool antigen or urea breath test (stop PPI 2 weeks, antibiotics/bismuth 4 weeks before to avoid false negative); or biopsy-based CLO/histology at OGD
  • FBC (anaemia), ferritin, U&E, LFTs, lipase if pain
  • Upper GI endoscopy (OGD): diagnostic and for alarm features; ALWAYS biopsy gastric ulcers (exclude malignancy) and repeat OGD at 6-8 weeks to confirm healing
  • Group & save / crossmatch + clotting if bleeding; use Glasgow-Blatchford score
  • Erect CXR / CT abdomen if suspected perforation (free air)
  • Fasting serum gastrin (off PPI) if multiple/refractory ulcers -> Zollinger-Ellison
  • Review drug chart: NSAIDs, aspirin, steroids, SSRIs, anticoagulants

Management

  • Resuscitate and treat complications first: bleeding ulcer -> ABC, IV access, transfuse to target, urgent OGD within 24h with endoscopic haemostasis + high-dose IV PPI; perforation -> surgical emergency (see separate protocols)
  • Stop NSAIDs/aspirin where possible; if aspirin needed for secondary cardiovascular prevention, restart with PPI cover once haemostasis secured
  • Start PPI to heal ulcer (duodenal 4 weeks, gastric 8 weeks)
  • Test for H. pylori in ALL PUD and eradicate if positive
  • Prescribe first-line eradication regimen (see drugs) for 14 days
  • Confirm eradication with urea breath test or stool antigen at least 4 weeks after completing therapy (and >2 weeks off PPI)
  • Repeat OGD at 6-8 weeks for all GASTRIC ulcers to confirm healing and exclude malignancy
  • If H. pylori negative and non-NSAID: continue PPI, consider gastrin (ZES), reassess adherence, consider idiopathic ulcer long-term PPI

Drugs & doses

FIRST-LINE eradication (ACG 2024, optimised bismuth quadruple, 14 days): PPI standard dose BD + bismuth subsalicylate/subcitrate 120-300 mg QDS + tetracycline 500 mg QDS + metronidazole 400-500 mg TDS-QDS for 14 days
Alternative first-line (ACG 2024): rifabutin triple - omeprazole 40 mg BD + amoxicillin 1 g TDS + rifabutin 50 mg TDS for 14 days
Alternative first-line: vonoprazan 20 mg BD + amoxicillin 1 g TDS (dual) for 14 days where vonoprazan available [verify local availability]
AVOID clarithromycin triple unless local clarithromycin resistance <15% or proven susceptibility (eradication falls to ~30% in resistant strains)
If penicillin-allergic: PPI BD + bismuth + tetracycline + metronidazole (bismuth quadruple, no amoxicillin)
Salvage after bismuth quad failure: rifabutin triple; or levofloxacin 500 mg OD + amoxicillin 1 g BD + PPI BD 14 days if levofloxacin-sensitive
Ulcer healing/maintenance PPI: omeprazole 20-40 mg OD, or pantoprazole 40 mg OD, or esomeprazole 40 mg OD (gastric ulcer 8 weeks, duodenal 4 weeks)
NSAID ulcer prophylaxis for ongoing high-risk NSAID users: PPI co-prescription (e.g. omeprazole 20 mg OD)

Disposition

Admit if bleeding, perforation or obstruction (surgical/endoscopy pathway). Otherwise outpatient: PPI course + eradication, GP follow-up, gastroenterology for repeat OGD of gastric ulcers and refractory/complicated disease.

Complications & pitfalls

  • Upper GI haemorrhage (most common complication)
  • Perforation (free intraperitoneal air, peritonitis)
  • Gastric outlet obstruction (chronic scarring)
  • Penetration into pancreas (refractory pain, raised lipase)
  • Gastric adenocarcinoma masquerading as benign ulcer

Exam pearls

  • ACG 2024 H. pylori guideline: optimised BISMUTH QUADRUPLE therapy x14 days is now the preferred first-line empiric regimen; clarithromycin triple only with proven susceptibility due to rising resistance.
  • ALWAYS confirm eradication (breath/stool test) >=4 weeks after therapy and >=2 weeks off PPI - do not assume cure.
  • ALL gastric ulcers need biopsy at index OGD AND repeat endoscopy at 6-8 weeks to confirm healing and exclude malignancy; duodenal ulcers usually do not.
  • In a bleeding ulcer do not delay H. pylori work-up - biopsy-based tests have lower sensitivity during acute bleed, so retest later if negative.
  • Co-prescribe a PPI with any patient who must continue NSAIDs/aspirin and has prior ulcer, age >65, or concomitant anticoagulant/steroid.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.